Trials / Withdrawn
WithdrawnNCT01206907
Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Opioid Tolerant Pediatric Subjects
AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER EFFECTIVENESS, SAFETY AND TOLERABILITY STUDY OF OXYMORPHONE HCl IMMEDIATE-RELEASE ORAL LIQUID IN OPIOID-TOLERANT PEDIATRIC SUBJECTS WITH CHRONIC PAIN REQUIRING AN AROUND THE CLOCK OPIOID
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Endo Pharmaceuticals · Industry
- Sex
- All
- Age
- 2 Years – 6 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness, tolerability, and safety of oxymorphone immediate release (IR) oral liquid as an analgesic in pediatric subjects having severe to moderate chronic pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | oxymorphone IR | oxymorphone IR liquid |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2010-09-22
- Last updated
- 2012-08-17
Source: ClinicalTrials.gov record NCT01206907. Inclusion in this directory is not an endorsement.